Author

Anisha Jain

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer

KRAS mutations, particularly KRAS G12C, pose significant therapeutic challenges in non-small cell lung cancer (NSCLC) due to limited inhibitor efficacy and rapid resistance. Drug repurposing offers a time and cost-effective strategy to identify alternative therapeutic options targeting KRAS-driven signalling. A structu...

Anisha Jain, Chandan Dharmashekar, B. S et al. · Scientific Reports · 0 citations

Open access Aug 2026

7-Deshydroxypyrogallin-4-carboxylic acid dietary phytochemical as a putative FTO inhibitor in breast cancer: an integrated computational and cytotoxicity study.

These findings provide a preliminary mechanistic and experimental framework for DCA as a dietary FTO inhibitor in breast cancer, necessitating further validation through orthogonal target engagement assays, m6A quantification, and in vivo tumor models.

Shuaib Pasha, S. Harishkumar, Revanth Handralu Chandraiah et al. · Naunyn-Schmiedeberg's Archiv... · 0 citations

Open access Aug 2026

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft

Background KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) is currently treated with KRAS G12C covalent inhibitors, such as sotorasib, or RAS (ON) G12-selective inhibitors; however, response rates and progression-free survival remain limited, with recurrence occurring in most patients. Although mechanisms...

Jessica González, Xue-Ting Cai, Wenjing Diao et al. · Neoplasia · 0 citations